Senior Scientist, In Vivo Translational Pharmacology

U175 (FCRS = US175) Novartis Institutes for BioMedical Research, Inc.; Cambridge (MA); On-site; USD 99,000 - 192,000; Full time

Benefits offered by this job

Performance-based incentive

401(k) with company match

Comprehensive benefits (health, life,

Job summary

Novartis Institutes for BioMedical Research, Inc. is seeking a Senior Scientist I or II in Cambridge, MA to lead in vivo studies across small molecules and biologics, including xRNA modalities.

You will design, execute, and interpret complex studies, partnering with project teams to drive target validation and therapeutic development. The role emphasizes scientific leadership, animal welfare, and 3Rs compliance, with opportunities to innovate phenotyping platforms and surgical models.

Qualifications

• Extensive experience in designing, executing, and interpreting in vivo pharmacology studies in drug discovery.
• Strong PK/PD and translational pharmacology expertise.
• Proficiency with data analysis tools and clear stakeholder communication.

Responsibilities

• Lead design, execution, and interpretation of complex in vivo studies across modalities.
• Develop translational study strategies and deliver decision-enabling datasets for project progression.
• Mentor and lead cross-functional teams while ensuring scientific rigor and compliance.

Skills

In vivo pharmacology

PK/PD

Data analysis

R/Python

Collaborative leadership

Education

Bachelor’s or Master’s in Biomedical Sciences

PhD considered (last 3 years)

Tools

R

Python

Job description

Novartis Institutes for BioMedical Research, Inc. is seeking a Senior Scientist I or II in Cambridge, MA to lead in vivo studies across small molecules and biologics, including xRNA modalities.

You will design, execute, and interpret complex studies, partnering with project teams to drive target validation and therapeutic development. The role emphasizes scientific leadership, animal welfare, and 3Rs compliance, with opportunities to innovate phenotyping platforms and surgical models.